van der Burg SH - Search Results

1

Melief CJ, van Hall T, Arens R, Ossendorp F, van der Burg SH. Melief CJ, et al. Among authors: van hall t, van der burg sh. J Clin Invest. 2015 Sep;125(9):3401-12. doi: 10.1172/JCI80009. Epub 2015 Jul 27. J Clin Invest. 2015. PMID: 26214521 Free PMC article. Review.

2

Characterization of cytotoxic T lymphocyte epitopes of a self-protein, p53, and a non-self-protein, influenza matrix: relationship between major histocompatibility complex peptide binding affinity and immune responsiveness to peptides.

Nijman HW, Houbiers JG, van der Burg SH, Vierboom MP, Kenemans P, Kast WM, Melief CJ. Nijman HW, et al. Among authors: van der burg sh. J Immunother Emphasis Tumor Immunol. 1993 Aug;14(2):121-6. J Immunother Emphasis Tumor Immunol. 1993. PMID: 7506574

3

Induction of a primary human cytotoxic T-lymphocyte response against a novel conserved epitope in a functional sequence of HIV-1 reverse transcriptase.

van der Burg SH, Klein MR, van de Velde CJ, Kast WM, Miedema F, Melief CJ. van der Burg SH, et al. Among authors: van de velde cj. AIDS. 1995 Feb;9(2):121-7. AIDS. 1995. PMID: 7536421

4

Cell-mediated autoimmunity in patients with Wegener's granulomatosis (WG).

Ballieux BE, van der Burg SH, Hagen EC, van der Woude FJ, Melief CJ, Daha MR. Ballieux BE, et al. Among authors: van der woude fj, van der burg sh. Clin Exp Immunol. 1995 May;100(2):186-93. doi: 10.1111/j.1365-2249.1995.tb03651.x. Clin Exp Immunol. 1995. PMID: 7743653 Free PMC article.

5

p53, a potential target for tumor-directed T cells.

Nijman HW, Van der Burg SH, Vierboom MP, Houbiers JG, Kast WM, Melief CJ. Nijman HW, et al. Among authors: van der burg sh. Immunol Lett. 1994 May;40(2):171-8. doi: 10.1016/0165-2478(94)90189-9. Immunol Lett. 1994. PMID: 8088874

6

In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild-type p53.

Houbiers JG, Nijman HW, van der Burg SH, Drijfhout JW, Kenemans P, van de Velde CJ, Brand A, Momburg F, Kast WM, Melief CJ. Houbiers JG, et al. Among authors: van der burg sh, van de velde cj. Eur J Immunol. 1993 Sep;23(9):2072-7. doi: 10.1002/eji.1830230905. Eur J Immunol. 1993. PMID: 8370389

7

Immunogenicity of peptides bound to MHC class I molecules depends on the MHC-peptide complex stability.

van der Burg SH, Visseren MJ, Brandt RM, Kast WM, Melief CJ. van der Burg SH, et al. J Immunol. 1996 May 1;156(9):3308-14. J Immunol. 1996. PMID: 8617954

8

Analogues of CTL epitopes with improved MHC class-I binding capacity elicit anti-melanoma CTL recognizing the wild-type epitope.

Bakker AB, van der Burg SH, Huijbens RJ, Drijfhout JW, Melief CJ, Adema GJ, Figdor CG. Bakker AB, et al. Among authors: van der burg sh. Int J Cancer. 1997 Jan 27;70(3):302-9. doi: 10.1002/(sici)1097-0215(19970127)70:3<302::aid-ijc10>3.0.co;2-h. Int J Cancer. 1997. PMID: 9033632 Free article.

9

Do epitopes derived from autoantigens display low affinity for MHC class I?

van der Burg SH, Visseren MJ, Offringa R, Melief CJ. van der Burg SH, et al. Immunol Today. 1997 Feb;18(2):97-8. doi: 10.1016/s0167-5699(97)84246-6. Immunol Today. 1997. PMID: 9057363 No abstract available.

10

HIV-1 reverse transcriptase-specific CTL against conserved epitopes do not protect against progression to AIDS.

van der Burg SH, Klein MR, Pontesilli O, Holwerda AM, Drijfhout JW, Kast WM, Miedema F, Melief CJ. van der Burg SH, et al. J Immunol. 1997 Oct 1;159(7):3648-54. J Immunol. 1997. PMID: 9317165

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

344 results

Search Page